Top Healthcare Stocks
Healthcare stocks were rebounding Tuesday following several days
of extended losses, with the NYSE Healthcare Sector Index adding
0.9% and shares of healthcare companies in the S&P 500 also
climbing 0.9% as a group.
In company news, Galectin Therapeutics (
) jumped as much as 27% Tuesday, more than recouping Monday's steep
slide in its share price after the biotech company said it will
release results from Phase I testing of its GR-MD-02 drug candidate
in patients with fatty liver disease with advanced fibrosis early
Investors leaped on the nearly one-week notice for a March 31
news release and a pre-market conference call by CEO Peter Taber on
April 1 as a positive omen for the drug. The company said it will
issue data from the first of three eight-person co-horts begun in
early January and randomized to have six patients treated with
GR-MD-02 and two others receiving a placebo.
The early-stage trial was intended to evaluate safety,
tolerability and efficacy of single and multiple doses of GR-MD-02,
a complex carbohydrate drug that targets a protein critical in the
pathogenesis of fatty liver disease and fibrosis. Pre-clinical data
has shown success for the drug reversing fibrosis and cirrhosis,
GALT shares were ahead 12.3% at $16.39 apiecein recent trade,
earlier climbing to an intra-day high of $18.61, up 27.6%. The
stock closed 6.5% lower Monday after the company reported a $21.9
million net loss, including one-time items, during 2013 compared
with a $10.9 million loss during the prior year period. It had no
The company late Friday also filed a shelf registration to sell
up to $100 million of its stock, debt or derivative securities.
Selling shareholders also may offer up to 500,000 additional
In other sector news,
(+) BGMD, Hits new 52-week high Tuesday after saying its BGM
Galectin-3 test during three clinical trials correctly identified
elevated levels of a protein marker in the bloodstream for severe
(-) PDEX, Launches offering to existing shareholders of
subscription rights to purchase a pro-rata portion of the company's
shares at $1.90 each by April 25. Proceeds will used to pursue
strategic opportunities and for working capital.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.